UCI Statement on Juan José Amador Castano, UCI Professional Continental Team Manzana Postobon and Alex Norberto Cano Ardila

May 20, 2019, 17:41 PM
The Union Cycliste Internationale (UCI) announces that the Colombian rider Juan José Amador Castano was notified of an Adverse Analytical Finding (AAF) for Boldenone in a sample collected during an out-of-competition control held on 22 October 2018.
 
The doping control was planned and carried out by the Cycling Anti-Doping Foundation (CADF), the independent body mandated by the UCI, in charge of defining and implementing the anti-doping strategy in cycling. 
 
The rider has the right to request and attend the analysis of his B sample. 
 
In accordance with UCI Anti-Doping Rules, the rider has been provisionally suspended until the adjudication of the affair. 
 
Juan José Amador Castano’s AAF constitutes the second AAF for a member of the UCI Professional Continental Team Manzana Postobon within a twelve-month period. On 5 April 2019, the UCI notified the Colombian rider Wilmar Andres Paredes Zapata of an AAF for Erythropoietin (EPO) in a sample collected during an out-of-competition control held on 27 February 2019. These two cases within the same twelve-month period trigger the application of article 7.12.1 of the UCI Anti-Doping Rules providing for the suspension of the Team from 15 days to 45 days.
 
The UCI will refer the matter to the Disciplinary Commission which will render a decision in due course.

The UCI also announces that the Colombian rider Alex Norberto Cano Ardila was notified of an Anti-Doping Rule Violation (Use of a prohibited substance) based on abnormalities detected in his Biological Passport (*).
 
In accordance with the UCI Anti-Doping Rules, the rider has been provisionally suspended until the adjudication of the affair. 
 
(*) An Athlete Biological Passport (ABP) is an individual, electronic record for each rider, in which the results of all doping tests collected in the framework of this programme over a period of time are collated. The management of the ABP programme is carried out by the Cycling Anti-Doping Foundation, the independent body mandated by the UCI to carry out the anti-doping testing programme in cycling. CADF handles the management of the ABP in collaboration with the APMU in Lausanne. ABP cases are prosecuted based on the opinion of an independent Expert Panel of the APMU.
 
At this stage, the UCI will not comment further on any of these matters.